Cynata Therapeutics Limited (CYYNF)
OTC GREY OTC GREY Primary Summary
Cynata Therapeutics Limited (CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation Transcript
Cynata Therapeutics Limited (OTCPK:CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation November 5, 2025 8:30 PM EST Company Participants Lauren Nowak Kilian Kelly - MD, CEO & Director Mathias Kroll - Chief Business Officer Presentation Lauren Nowak All right, seems like everybody has managed to make their way. So I just wanted to say good morning, and thank you for joining Cynata Therapeutics Investor Webinar for the September 2025 quarter.
Cynata Therapeutics Limited (CYYNF) Q4 2025 Earnings Call Transcript
Cynata Therapeutics Limited (OTCPK:CYYNF) Q4 2025 Earnings Conference Call August 4, 2025 9:00 PM ET Company Participants Kilian Kelly - MD, CEO & Director Mathias Kroll - Chief Business Officer Kilian Kelly [Starts Abruptly] for now, just to explain that we will go through a fairly brief presentation, just to summarize the key highlights of the recently completed quarter. And following that, we'll have a Q&A session.
Cynata Therapeutics Limited (CYYNF) Investor Webinar Transcript
Cynata Therapeutics Limited (OTCPK:CYYNF) Investor Webinar Conference Call February 5, 2025 6:30 PM ET Company Participants Lauren Nowak - Media Relations Kilian Kelly - Chief Executive Officer and Managing Director Mathias Kroll - Chief Business Officer Geoff Brooke - Independent Non-Executive Chairman Conference Call Participants Lauren Nowak Okay. Great. Let's get going.
Cynata Therapeutics Limited (CYYNF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Cynata Therapeutics Limited ever had a stock split?
Cynata Therapeutics Limited Profile
| Biotechnology Industry | Healthcare Sector | Dr. Kilian Kelly CEO | OTC GREY Exchange | AU000000CYP7 ISIN |
| Australia Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Cynata Therapeutics Limited, operating within Australia, is at the forefront of developing and commercializing innovative stem cell technologies aimed at human therapeutic use, specifically through its proprietary Cymerus brand. This brand leverages cutting-edge induced pluripotent stem cell and mesenchymal stem cell technology to address a broad spectrum of diseases. Initially known as Eco Quest Limited, the company underwent a name change to Cynata Therapeutics Limited in October 2013. Since its inception in 2003, it has been committed to advancing stem cell treatment, underlining its dedication through a strategic partnership with Fujifilm, which focuses on the clinical and commercial manufacturing, as well as supply of Cynata’s therapeutic mesenchymal stem cell products.
Products and Services
- CYP-001
This leading therapeutic product candidate of Cynata has successfully completed Phase I clinical trials, showcasing its potential in the treatment of graft versus host disease. This promising development indicates Cynata’s capability in addressing complex post-transplant complications using stem cell technologies.
- CYP-004
Currently in Phase III clinical trial, CYP-004 is being developed as a groundbreaking treatment for osteoarthritis. This underscores Cynata’s dedication to tackling prevalent, debilitating conditions through advanced stem cell therapy solutions.
- CYP-006TK
This novel product is a polymer-coated silicon wound dressing specifically designed for diabetic wounds, representing Cynata’s innovative approach to wound care and its commitment to improving outcomes for patients with diabetes-related complications.
- Other Developments
Alongside its primary candidates, Cynata is also pushing the boundaries in stem cell therapy by developing treatments for a wide array of conditions including asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. These efforts reflect the broad applicability of Cynata’s Cymerus technology across different medical fields, underscoring the company's role in potentially revolutionizing the healthcare landscape.
